-
Mashup Score: 7
Objective To assess the risk of serious infection associated with different targeted therapies for psoriatic arthritis (PsA) in real-world settings. Methods This nationwide cohort study used the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database to identify all adults with PsA who were new users of targeted therapies (adalimumab, etanercept, golimumab, certolizumab pegol, infliximab, secukinumab, ixekizumab, ustekinumab, and tofacitinib) from 1 January 2015 to 30 June 2021. The primary outcome was a serious infection (ie, requiring hospitalisation), in a time-to-event analysis using propensity score-weighted Cox models, with adalimumab as the comparator, estimating weighted HRs (wHRs) and their 95% CIs. Results A total of 12 071 patients were included (mean age 48.7±12.7 years; 6965 (57.7%) women). We identified 367 serious infections (3.0% of patients), with a crude incidence rate of 17.0 per 1000 person-years (95% CI, 15
Source: rmdopen.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 4The worldwide prevalence of psoriatic arthritis—a systematic review and meta-analysis - 1 month(s) ago
AbstractObjectives. Previous attempts to pool prevalence studies in PsA have failed to take account of important methodological differences between studies
Source: academic.oup.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1Advanced therapy not enough for nearly 75% of Canadian patients with psoriatic arthritis - 1 month(s) ago
Patients with psoriatic arthritis in Canada face “substantial burden and unmet need” for improved treatments, as nearly 75% fail to achieve minimal disease activity within 6 months of starting advanced therapy, according to data. “Although there has been great progress in the management of patients with psoriatic arthritis, there is a larger proportion of patients who either do
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 2Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial - 1 month(s) ago
Rheumatology and Therapy – Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating…
Source: link.springer.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 2
Objective To assess the risk of serious infection associated with different targeted therapies for psoriatic arthritis (PsA) in real-world settings. Methods This nationwide cohort study used the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database to identify all adults with PsA who were new users of targeted therapies (adalimumab, etanercept, golimumab, certolizumab pegol, infliximab, secukinumab, ixekizumab, ustekinumab, and tofacitinib) from 1 January 2015 to 30 June 2021. The primary outcome was a serious infection (ie, requiring hospitalisation), in a time-to-event analysis using propensity score-weighted Cox models, with adalimumab as the comparator, estimating weighted HRs (wHRs) and their 95% CIs. Results A total of 12 071 patients were included (mean age 48.7±12.7 years; 6965 (57.7%) women). We identified 367 serious infections (3.0% of patients), with a crude incidence rate of 17.0 per 1000 person-years (95% CI, 15
Source: rmdopen.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 13
We aimed to analyze the clinical characteristics of patients with psoriasis and determine the predictive factors of psoriatic arthritis (PsA).This retrospective cohort study was performed among patients with psoriasis. Demographic and clinical data were …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Diane’s Story: It’s Never Too Late to Start Getting Good Care - The Psoriatic Arthritis Club - 3 month(s) ago
Diane should have been diagnosed with PsA well before she actually was. As a woman of color who grew up poor, she endured decades of inadequate treatment, misdiagnosis, and stigma. But she also learned a lot about how to turn things around and advocate for better care. “Someone told me a bunch of years ago, you have a voice, use it,” Diane says. “That had to be the best advice ever. Use your voice.”
Source: omny.fmCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 18
We aimed to analyze the clinical characteristics of patients with psoriasis and determine the predictive factors of psoriatic arthritis (PsA).This retrospective cohort study was performed among patients with psoriasis. Demographic and clinical data were …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 2Sleep Problems in Patients With Psoriatic Arthritis: A Systematic Literature Review and Metaanalysis - 5 month(s) ago
Objective The aim of this systematic review and metaanalysis is to summarize evidence regarding the relationship between psoriatic arthritis (PsA) and sleep problems. Methods We identified 36 eligible studies—26 cross-sectional, 7 cohort, and 3 interventional studies—in PubMed and Embase. Results The prevalence of self-reported sleep problems in patients with PsA ranged from 30% to 85%. A metaanalysis of 6 studies that used the Pittsburgh Sleep Quality Index revealed a prevalence of poor sleep quality for patients with PsA of 72.9% (95% CI 63-81.8; I 2 = 78%), which was statistically higher than in healthy controls (26.9%, 95% CI 11.7-45.4; I 2 = 81%) but not significantly different than in patients with psoriasis (59.8%, 95% CI 46.9-72.1; I 2 = 51%). Sleep disturbance was ranked in the top 4 health-related quality of life domains affected by PsA. One study suggested a bidirectional relationship between PsA and obstructive sleep apnea. Predictors of sleep problems included anxiety, pai
Source: www.jrheum.orgCategories: General Medicine News, RheumatologyTweet-
Metanalysis shows the prevalence of self-reported sleep problems in #PsA ranged 30% to 85%. 6 studies showed poor sleep quality in 73% (statistically higher than controls 27%). Sleep ranked in the top 4 health-related quality of life domains by PsA pts. https://t.co/d79Ji3KCBu https://t.co/HJpqUIQ8x6
-
-
Mashup Score: 3Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study - 5 month(s) ago
Objectives To compare all-cause mortality and causes of death between patients with psoriatic arthritis (PsA) and the general population in Sweden. Methods Adults with at least one main PsA diagnosis (International Classification of Diseases-10: L40.5/M07.0–M07.3) from outpatient rheumatology/internal medicine departments 2001–2017 were identified from the National Patient Register. Each case was matched to five population comparator-subjects on sex/county/age at the case’s first arthritis diagnosis. Follow-up ran from 1 January 2007, or from first PsA diagnosis thereafter, until death, emigration or 31 December 2018. Mortality was assessed overall, and stratified by sex and duration since diagnosis (diagnosis before/after 1 January 2007), using matched Cox proportional hazard regression (excluding/including adjustments for comorbidity) or Breslow test, as appropriate. Incidence rate ratios (IRR) of death, overall and stratified by sex/duration since diagnosis/age, as well as causes of
Source: ard.bmj.comCategories: General Medicine News, General HCPsTweet
French insurance claims study of 12071 #PsA pts on biologics (2015-2021) found total of 367 serious infections (3%; IR 1.7/100PY). SIR risk significantly lower for new users of etanercept (wHR 0.72) & ustekinumab (wHR 0.57) (vs ADA new users https://t.co/CutqoxA05e https://t.co/OUCUbrKnFF